GPCR

16.2405.14%
EL

Eric L. Dobmeier

Independent Director

Mr. Eric L. Dobmeier, J.D., is Independent Chairman of Jade Biosciences, Inc. and serves as a member of its Board since October 2024. Mr. Dobmeier is Lead Independent Director at Bluejay Therapeutics from November 2024. He is Venture Partner of Samsara BioCapital LLC from 2024. He joined the Samsara BioCapital LLC in 2024. He is an Independent Director of Janux Therapeutics, Inc. from July 2024. He is Director of Abdera Therapeutics Inc. from January 2024. He has been an Independent Director at Structure Therapeutics Inc. since December 2022. He was the President, Chief Executive Officer and Director of Chinook Therapeutics, Inc. since April 2019 until August 11, 2023. From January 2018 to June 2018, he was President and Chief Executive Officer of Silverback Therapeutics, Inc. He also served as an Independent Director of Adaptive Biotechnologies Corporation since September 2016 until March 17, 2021. He served as Director of Versartis, Inc. since May 25, 2017 unitl October 12, 2018. He served as the Chief Operating Officer of Seattle Genetics, Inc. from June 17, 2011 to December 14, 2017 and served as its Corporate Secretary from March 2002 to November 2014. Mr. Dobmeier served as the Chief Business Officer of Seattle Genetics Inc. from May 2007 to June 17, 2011. He serves with Seattle Genetics in March 2002 until 2017 and managed its business development, legal, corporate communications, strategic marketing and project management groups. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the ex-U. S./Canada development and commercialization agreement with Takeda Pharmaceutical Company for ADCETRIS, the global co-development and co-commercialization agreement for enfortumab vedotin with Astellas Pharma and multiple ADC collaborations with leading biotechnology and pharmaceutical companies. Mr. Dobmeier served as General Counsel of Seattle Genetics Inc. from March 2002 to September 2006. He served as a Vice President of Corporate Affairs at Seattle Genetics Inc. from September 2003 to November 2005, Senior Vice President of Corporate Development since February 28, 2005 until 2008 and Senior Director of Legal Affairs from March 1998 to March 2002. Mr. Dobmeier served as an Attorney and then a Senior Attorney of Venture Law Group, a law firm, from March 1998 to March 2002. Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP. He is currently a venture partner at Samsara Biocapital. He served as an Associate of Heller Ehrman White & McAuliffe, a law firm, from January 1997 to February 1998, where he represented technology companies in connection with public and private financings, mergers & acquisitions and corporate Partnering transactions. He also served as a Judicial Law Clerk of Honorable Spencer M. Williams of the U. S. District Court for the Northern District of California from September 1994 to October 1996. He had been a Director of Atara Biotherapeutics, Inc. since March 27, 2015 until June 10, 2024. He was an Independent Director of Stemline Therapeutics, Inc. since April 2012 until June 21, 2018. He currently serves on the boards of directors of Janux Therapeutics and several private biotechnology companies. Mr. Dobmeier holds a JD from Boalt Hall School of Law, University of California, Berkeley School of Law and an A. B. in History from Princeton University.

公司職務